Endometrial mesonephric-like adenocarcinoma: Clinicopathologic features, treatment, and outcomes
Open Access
- 5 November 2025
- journal article
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 26 (4) , 668-678
Abstract
Endometrial mesonephric-like adenocarcinoma (MLA) is a rare subtype of uterine corpus endometrial carcinoma (UCEC) first described in 2016. The clinicopathological features, treatment options, and prognosis of endometrial MLA remain poorly understood. In this study, we retrospectively analyzed the clinicopathological characteristics, molecular features, treatment regimens, and outcomes of 11 patients diagnosed with endometrial MLA. The most prevalent symptom observed was postmenopausal bleeding. Notably, 78% (7 out of 9) of patients were diagnosed at advanced FIGO stages (II-IV), with four cases presenting with distant metastasis upon initial examination. Multivisceral metastases were identified in three cases, with lung metastases being the most common, occurring in 45% of patients. The median progression-free survival (PFS) was 16 months (95% confidence intervals: 6-26). All tumors tested negative for progesterone receptors (PR), while 91% of patients (10 out of 11) were negative for estrogen receptors (ER). Most patients exhibited positive immunohistochemical staining for "mesonephric-like" markers, including GATA-binding protein 3 (GATA-3), thyroid transcription factor-1 (TTF-1), and CD10. Furthermore, 91% of patients showed a wild-type p53 immunostaining pattern. Among the 11 patients, five underwent KRAS mutation testing, revealing KRAS mutations in all tested individuals (p.G12D in 2/5, p.G12A in 1/5, p.G12V in 1/5, and p.G13D in 1/5). These findings indicate that 78% of endometrial MLA patients were diagnosed at an advanced stage and suggest that this subtype may exhibit more aggressive behavior compared to endometrial endometrioid carcinoma. The consistent presence of KRAS mutations in patients who underwent testing highlights the potential role of KRAS in the initiation and progression of endometrial MLA, positioning it as a promising therapeutic target.Keywords
This publication has 33 references indexed in Scilit:
- Clinicopathologic and Molecular Characteristics of Mesonephric Adenocarcinoma Arising From the Uterine BodyAmerican Journal of Surgical Pathology, 2019
- A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic TractAmerican Journal of Surgical Pathology, 2018
- Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancerJournal of Experimental & Clinical Cancer Research, 2018
- Characterization of distinct types of KRAS mutation and its impact on first‑line platinum‑based chemotherapy in Chinese patients with advanced non‑small cell lung cancerOncology Letters, 2017
- Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2016
- Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screeningScientific Reports, 2016
- Hormone receptor‐negative, thyroid transcription factor 1‐positive uterine and ovarian adenocarcinomas: report of a series of mesonephric‐like adenocarcinomasHistopathology, 2016
- Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancerJournal of Cancer Research and Clinical Oncology, 2014
- A Report of Eight Cases, Including Four with a Malignant Spindle Cell ComponentAmerican Journal of Surgical Pathology, 1995
- Mesonephric Remnants, Hyperplasia, and Neoplasia in the Uterine CervixAmerican Journal of Surgical Pathology, 1990